Sekisui XenoTech adds new test systems to service offerings

By Melissa Fassbender contact

- Last updated on GMT

Sekisui XenoTech adds new test systems to service offerings

Related tags: Contract research organization, Pre-clinical development

Sekisui XenoTech has added new dermal subcellular fraction test systems to its contract research services.

Subcellular fractions are used in drug discovery and preclinical drug development to evaluate a new therapeutics’ in vitro​ metabolism.

According to the contract research organization (CRO), human and minipig have been added to the company’s list of species with dermal subcellular fractions available as standard test systems.

Our biggest demand so far has come from European countries where animal use in biomedical/cosmetic research is highly restricted and most testing has to be performed in vitro​,” Zell Woodworth, Products Division Director for Sekisui XenoTech, told us.

Generally, customers who are interested in skin subcellular fractions are looking for local substrate loss or metabolite formation in the skin during transdermal/topical delivery of a drug,​” Woodworth added.

Late last year, Sekisui XenoTech also expanded​ its test systems to include hepatic human lysosomes and rat tritosomes.

Additionally, in August of last year, the company announced​ supplementary hepatotoxicity screening assays and methodologies to its existing cytotoxicity contract research services. 

(Feature image: Sekisui XenoTech)

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related products

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Related suppliers

Follow us

Products

View more

Webinars